Mangalam Drugs And Organics working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
281.03×281.03×286.17×194.89×
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
62.40×62.40×38.43×36.88×
194.35×194.35×171.23×121.63×
149.08×149.08×153.37×110.14×
−5.69×−5.68×43.10×30.87×
0.68×0.68×0.91×1.06×
−0.09×−0.09×6.34×1.22×
−0.28×−0.28×1.19×−0.64×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MANGALAM₹29.22

Mangalam Drugs And Organics Limited

· Pharma & Health
₹ CrorePeersBIOFILCHEMLASAVINEETLABORTINGLOBEKREBSBIOALPABALPHARMANATCAPSUQMcap ₹46.3 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)—194.89286.17281.03281.03
Receivable Days (DSO)—36.8838.4362.4062.40
Payable Days (DPO)—121.63171.23194.35194.35
Cash Conversion Cycle (days)—110.14153.37149.08149.08
Working Capital Turnover—30.8743.10-5.68-5.69
Asset Turnover—1.060.910.680.68
Cash Conversion (CFO/Net Income)—1.226.34-0.09-0.09
CFO/EBITDA—-0.641.19-0.28-0.28
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.